Comparative characteristic of clinical efficacy of the original drug Movalis and its generic Amelotex in the treatment of non-specific lumbar pain

Yakovlev E.V.; Leontiev O.V.; Zhivolupov S.A.; Gnevyshev E.N.; Smirnov A.A.; Zhivolupova Y.A.; Samartcev I.N.

doi:https://doi.org/10.17116/jnevro202012007156

Yakovlev E.V.

Medical Center of JSC «Admiralteyskie Verfi»;
Institute of Applied Psychoanalysis and Psychology, University of the Interparliamentary Assembly of the Eurasian Economic Community

Leontiev O.V.

Nikiforov All-Russian Center for Radiation and Extreme Medicine, EMERCOM of Russia

Zhivolupov S.A.

Kirov Military Medical Academy

Gnevyshev E.N.

Institute of Applied Psychoanalysis and Psychology, University of the Interparliamentary Assembly of the Eurasian Economic Community;
rd Military Hospital of the National Guard of the Russian Federation

Smirnov A.A.

National Medical Research Center for Therapy and Preventive Medicine

ORCID: 0000-0002-6061-2565

Zhivolupova Y.A.

Saint Petersburg Electrotechnical University «LETI»

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Comparative characteristic of clinical efficacy of the original drug Movalis and its generic Amelotex in the treatment of non-specific lumbar pain

Authors:

Yakovlev E.V., Leontiev O.V., Zhivolupov S.A., Gnevyshev E.N., Smirnov A.A., Zhivolupova Y.A., Samartcev I.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 56‑62

DOI: 10.17116/jnevro202012007156

Read: 44841 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Yakovlev EV, Leontiev OV, Zhivolupov SA, Gnevyshev EN, Smirnov AA, Zhivolupova YA, Samartcev IN. Comparative characteristic of clinical efficacy of the original drug Movalis and its generic Amelotex in the treatment of non-specific lumbar pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):56‑62. (In Russ.)
https://doi.org/10.17116/jnevro202012007156

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To perform a comparative analysis of the efficacy of the original drug meloxicam (movalis) and its generic (amelotex) in the treatment of patients with lower back pain.

MATERIALS AND METHODS

The analysis of treatment results of 112 (61 men and 51 women) employees of JSC «Admiralteyskie Verfi», aged 18 to 60 years, was carried out. All these patients were treated in the period from 2015 to 2017 at the Medical Center of JSC «Admiralteyskie Verfi» due to dorsalgia of lumbosacral localization (ICD-10, item M54). The average age of the patients was 42,6±10,4 (from 22 to 59 years). Age range of patients was 20—35 years (n=34); 36—50 years (n=49); >50 years (n=29).

RESULTS

Compared to amelotex, movalis was more effective for the duration of pain intensity reduction (5±1,4 days (min 3, max 9) in the movalis group and 7,37±1,68 days (min 3, max 10) in the amelotex group) as well as for the total duration of temporary disability (labor losses 6,43±1,4 days (min 4, max 10) and 8,61±1,59 days (min 5, max 12), respectively). In addition, patients receiving movalis showed a more significant improvement in the Clinical Global Impression (CGI) score in all age groups compared with patients in the amelotex group.

CONCLUSION

The lack of therapeutic equivalence between movalis and amelotex determines the relevance of the drug choice for complex therapy of these patients, which will improve the prognosis of the disease and the quality of life of the patient.

Keywords:

dorsalgia

lower back pain

non-steroidal anti-inflammatory drugs

meloxicam

clinical effectiveness of treatment

Authors:

Yakovlev E.V.

Medical Center of JSC «Admiralteyskie Verfi»;
Institute of Applied Psychoanalysis and Psychology, University of the Interparliamentary Assembly of the Eurasian Economic Community

Leontiev O.V.

Nikiforov All-Russian Center for Radiation and Extreme Medicine, EMERCOM of Russia

Zhivolupov S.A.

Kirov Military Medical Academy

Gnevyshev E.N.

Smirnov A.A.

National Medical Research Center for Therapy and Preventive Medicine

ORCID: 0000-0002-6061-2565

Zhivolupova Y.A.

Saint Petersburg Electrotechnical University «LETI»

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Received:

25.05.2020

Accepted:

16.06.2020

Close metadata

References:

Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, Kerns R, Von Korff M, Porter L, Helmick C. Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:1001-1006. https://doi.org/10.15585/mmwr.mm6736a2. PMID: 30212442. PMCID: PMC6146950.
Gaskin DJ, Richard P. The Economics costs of pain in the United States. J. Pain. 2012;13(8):715. https://doi.org/10.1016/j.pain.2012.03.009
Baron R, Binder A. How neuropathic is sciatica? The mixed pain concept. Ortopade. 2004;33:568-575. https://doi.org/10.1007/s00132-004-0645-0. PMID: 15067505.
Popelyansky YYu. Vertebrogenic diseases of the nervous system. A guide for doctors and students. T.2. Pelviomembrane syndromes of lumbar osteochondrosis. Part 1. Clinic, etiology, pathogenesis. Yoshkar-Ola: Mari Publishing House, 1983;372. (In Russ.).
Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. https://doi.org/10.1002/14651858.CD000396
Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2(2):CD012087. Published 2016 Feb 10. https://doi.org/10.1002/14651858.CD012087
Zhukova DYa, Kovalskaya GN. Original and generic drugs in therapeutic practice. Siberian Medical Journal. 2011;7:96-102. (In Russ.).
Zhivolupov SA, Samartsev IN, Yakovlev EV. The main directions in optimizing the treatment of pain syndromes in neurological patients: neurophysiological analysis, topical nosological interpretation, the algorithm for the formation of complex modifying therapy. Consilium Medicum. 2014;2:15-23. (In Russ.).
Downie AS, Hancock MJ, Rzewuska M, Williams C, Lin CW, Maher C. Trajectories of acute low back pain: a latent class growth analysis. Pain. 2016 Jan;157(1):225-234. https://doi.org/10.1097/j.pain.0000000000000351. PMID: 26397929.
Acute nonspecific (musculoskeletal) lumbar pain. Recommendations of the Russian Society for the Study of Pain (ROIB). Neurology, neuropsychiatry, psychosomatics. 2018;10(2):4-11. (In Russ.).
Belousov YuB, Gurevich KG. General and private clinical pharmacology. M. Remediium, 2006;807.
Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Bégaud B, Dequeker J, Isomäki H, Littlejohn G, Mau J, Papazoglou S. Gastrointestinal tolerability of meloxicam compared to diclofenac in ostheoarthritis patients. International MELISSA Study Group. Meloxicam Large Scale International Study Safety Assesment. Br J Rheumatol. 1998 Sep;37(9):937-945. https://doi.org/10.1093/rheumatology/37.9.937. PMID: 9783757.
Chichasova NV. Effectiveness and safety of Movalis in the treatment of diseases of the musculoskeletal system. Pharmateka. 2009;11:28-33. (In Russ.).
Podchufarova EV, Yakhno NN. Application of amelotex for the treatment of patients with acute musculoskeletal back pain and grade 1 hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):46-52. (In Russ.). https://doi.org/10.14412/2074-2711-2011-166